N.J. Should Reject Blanket Menthol Bans

Industry Insight
Jul.21.2022

Hot on the heels of the Food and Drug Administration’s proposed ban on menthol-flavored tobacco products in April, some lawmakers in New Jersey apparently believe they can implement a ban sooner. Instead of rushing headlong, all advocates should stop to consider the potential negative consequences for public health, freedom and racial justice.

 

N.J. Should Reject Blanket Menthol Bans

Earlier this month, New Jersey’s Assembly Health Committee voted in favor of a statewide ban on the sale of menthol products under penalty of civil fines of up to $1,000. The proposed rule would have to clear the state Assembly and Senate before heading to the governor’s desk for signature.

 

Advocates of this bill emphasize the popularity of the menthol flavor, which cools otherwise harsh cigarette smoking. Theoretically, menthol makes smoking easier for new smokers and smokers struggling to quit. Proponents believe a menthol ban would disincentivize tobacco, thus increasing the smoking quit rate and so benefit public health.

 

This theory was recently challenged in a Journal of the National Cancer Institute survey of 16,000 smokers, which “revealed similar quit rates among menthol and non-menthol smokers.”

 

Equally important,  this study also warned about menthol bans leading smokers to substitute their menthol cigarettes with potentially more harmful tobacco products — “if, as a meta-analysis suggests, lung cancer risk is higher for non-menthol smokers.”

 

Studies that make the claim that menthol bans increase quit rates often neglect substitution — whether smokers who stopped smoking menthol quit smoking entirely or switched to other products.

 

For example, a recent article in the Journal of the American Medical Association found that the United Kingdom’s 2020 menthol ban was followed by a drop from 12 percent to 3 percent use of menthol among more than 7,000 teenage smokers. After listing competing studies, however, the paper left the substitution issue for “further research.”

 

Another recent paper reported that among more than 2,300 smokers, Canada’s 2015-2018 menthol ban saw a 21 percent to 22 percent cigarette quit rate among menthol users, compared with 7 to 8 percentage points less among non-menthol users. But what of substitution? Did smokers quitting cigarettes switch to flavored cigars or e-cigarettes, which are generally legalin Canada?

 

The ability to substitute with other, preferably safer, products is key to harm reduction, the policy designed to reduce the harm of destructive behaviors. Though substantial populations of American smokers say they would consider substitution in the wake of a menthol ban, U.S. lawmakers and regulators often outright oppose safer alternatives like e-cigarettes, particularly flavored brands, which, as studies overwhelmingly show, are healthier substitutes for everyone and help more smokers quit. Without a safety valve, as San Francisco discovered in a major study of teen smoking after its ban of all flavored products, cigarette use may “more than double.”

 

The FDA’s review of whether e-cigarettes can remain on the market has yet to approve menthol e-cigarettes. “Without this option,” argued a recent Wall Street Journal column, “menthol smokers may be tempted to tap the illicit market or self-mentholate regular cigarettes” — as in the U.K. and European Union after the 2020 E.U. ban. As the Wall Street Journal column suggested, smokeless alternatives like e-cigarettes or tobacco pouches would not only be safer but may also be an alternative revenue source that stunts tobacco companies’ resistance to menthol bans.

 

Other concerns with a blanket menthol ban abound. Dr. Jeffrey A. Singer, a general surgeon and senior fellow at the libertarian Cato Institute, recently amassed a large body of scientific literature to argue that menthol products are actually “no more addictive than non-menthol cigarettes, are associated with less tobacco consumption, and maybe even a lower cancer risk.” Singer also questioned the need for a menthol ban by presenting evidence that youth smoking is at an all-time low and rapidly decreasing. At the same time, 60 percent of teen smokers don’t even prefer menthol cigarettes.

 

None of this even considers broader policy or philosophical questions. Serious consideration of a menthol ban must account for its likely disparate racial enforcement. The ban’s paternalism also bespeaks illiberal intolerance and an uncomfortable classism.

 

Without a sober accounting of these potential harms from menthol bans, politicians should kick their unhealthy prohibition habit. If they don’t, New Jersey voters should kick them out.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

Also read:

Juul Gets Temporary Reprieve to Keep Selling Its E-Cigarettes

China’s Zhengzhou Tobacco Research Institute develops end-to-end heated tobacco analysis to trace aerosol compound origins
China’s Zhengzhou Tobacco Research Institute develops end-to-end heated tobacco analysis to trace aerosol compound origins
The Zhengzhou Tobacco Research Institute of China National Tobacco Corporation has filed a patent application for an end-to-end method to analyze the migration and transformation of chemical compounds in heated tobacco products. Using GC-Orbitrap/MS non-targeted analysis, the method compares tobacco substrate and aerosol samples to distinguish compounds transferred directly from the substrate from those newly formed during heating, while also calculating transfer rates. In an example involving nine heated tobacco products, the patent identified 17 newly formed thermal decomposition compounds and 38 transferred compounds.
Aug.13
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
As JUUL2 Wins FDA Authorization, Harm Reduction Journal Highlights the Role of Real-World Evidence in Nicotine Product Regulation
A commentary published in the international open-access, peer-reviewed Harm Reduction Journal argues that randomized controlled trials remain central to evaluating smoking cessation efficacy but cannot alone capture real-world uptake, complete switching, longer-term use and population impact of non-combustible nicotine products such as e-cigarettes, heated tobacco and nicotine pouches. The authors frame impact as “reach × efficacy” and call for real-world evidence to complement RCTs. Three days after publication, the FDA authorized three JUUL2 products and highlighted complete switching among adult smokers in explaining its decision, providing a timely regulatory backdrop to the debate.
Sep.08
Philippines Customs Seizes PHP11.68 Billion($200 Million) in Illegal Tobacco and Vapes in First Seven Months of 2026
Philippines Customs Seizes PHP11.68 Billion($200 Million) in Illegal Tobacco and Vapes in First Seven Months of 2026
Philippines Customs data showed that illegal cigarettes and vape products seized during the first seven months of 2026 were valued at about PHP11.68 billion, exceeding the PHP2.516 billion recorded for the full year of 2025. The figures were disclosed by a Bureau of Customs official during a House Committee on Ways and Means hearing on tobacco excise tax reforms. Vape-related seizures were valued at about PHP1.65 billion, with most cases recorded at the Manila International Container Port. Customs officials said enforcement against illicit tobacco trade would continue.
Aug.26
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
Wall Street Journal: U.S. FDA Plans Faster Vape and Nicotine Pouch Reviews, Revisit of 2021 PMTA Rule
The Trump administration is preparing changes intended to accelerate FDA market authorization reviews for e-cigarettes and nicotine pouches, according to The Wall Street Journal. The FDA is expected to revisit its 2021 PMTA rule and may simplify some scientific study requirements and shorten review times. The agency has not formally announced the changes. Over the past year, the FDA has already accelerated nicotine-pouch reviews, expanded ENDS authorizations and upgraded its CTP Portal NextGen application system. As of August 2026, 43 nicotine pouch products and 48 e-cigarette products had received FDA marketing authorization.
Sep.24
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang files patent for pressure-triggered, on-demand oral nicotine release
China Tobacco Zhejiang Industrial Co., Ltd. has filed a patent application for an oral nicotine delivery product designed to let users actively adjust nicotine release. The product embeds two types of nicotine reservoirs with different wall thicknesses and positions inside a deformable matrix. Pressure applied with the tongue or lips can rupture the reservoirs and accelerate nicotine release. In simulated oral tests, several patent examples showed sharply higher peak nicotine release rates as applied force increased from 0 N to 1 N and 3 N. The filing explores a shift from preset release profiles toward user-triggered nicotine delivery.
Sep.01
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
FRE and ALP Push Modern Oral to 48% of Q2 Sales as Turning Point Brands Changes CEO and Lowers Profit-Guidance Ceiling
Turning Point Brands said Executive Chairman David E. Glazek will become CEO on October 1, replacing Graham Purdy, who is stepping down for personal reasons. The company narrowed its 2026 adjusted EBITDA outlook to $70 million-$80 million from $70 million-$90 million while maintaining Modern Oral gross sales guidance of $330 million-$350 million and net sales guidance of $260 million-$270 million. In the second quarter, Modern Oral net sales rose 128% to $68.4 million and accounted for 48% of company-wide net sales. Adjusted EBITDA fell 50% year over year. TPB shares closed about 10% lower on September 21.
Market
Sep.22 by 2Firsts Perspectives